622: Outcomes of expectantly managed parturients after betamethasone for preeclampsia

Abstract

thy, coagulation disorders, preexisting thrombocytopenia, or anticoagulation were excluded. Subjects (n 100) were categorized into 4 groups of preeclampsia severity: preeclampsia, severe preeclampsia, severe preeclampsia with thrombocytopenia or renal dysfunction, and HELLP syndrome. We compared the mean and median TEG parameters (R time, K, angle, and MA) across strata of disease severity. Mean R values were compared with ANOVA. Median K, angle, and MA values were compared with Kruskal-Wallis. RESULTS: Comparing TEG parameters, the mean R value, a measure of clotting time, was not different across severity strata. The median K value, a measure clot strength, was different, with increasing time to achieve clot strengthening with increasing severity stratum. The median angle, a measure of rapidity of fibrin cross-linking, was different, with the slowest clot strengthening noted in patients with HELLP syndrome. The median MA, or maximum clot strength, a measure of platelet function, was different, with decreasing platelet function with increasing severity stratum. CONCLUSION: The K time, angle, and MA differed with worsening preeclampsia disease severity, indicating slower clot strengthening, and impaired fibrin cross-linking and clot strength with worsening preeclampsia.